The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients

Elisa Teyssou[1]*, Cathia Soulie[1]*, Benoit Visseaux[2], Sidonie Lambert-Niclot[3], Valentine Ferre[2], Stéphane Marot[1], Aude Jary[1], Sophie Sayon[1], Karen Zafilaza[1], Valentin Leducq[1], Aurélie Schnuriger[4], Marc Wirden[1], Nadhira Houhou-Fidouh[2], Charlotte Charpentier[2], Laurence Morand-Joubert[3], Sonia Burrel[1], Diane Descamps[2], Vincent Calvez[1], Anne Geneviève Marcelin[1]

[1] Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, laboratoire de virologie, F-75013, Paris, France ; [2] Service de Virologie, Université de Paris INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, F-75018 Paris, France ; [3] Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Universitaire Saint Antoine, laboratoire de virologie, F-75012, Paris, France ; [4] AP-HP, Hôpital Universitaire Armand-Trousseau, laboratoire de virologie, F-75012, Paris.

Keywords: SARS-CoV-2, variants, 501Y.V1, 501Y.V2, viral load.

Corresponding author: Dr Elisa Teyssou

Mailing address: Department of Virology, Pitié-Salpêtrière Hospital, 83 Boulevard de l'Hôpital, 75013 Paris, France. Phone: 33142177401, Fax: 33142177411.

e-mail : elisa.teyssou@aphp.fr

Abstract

The 501Y.V2 and the 501Y.V1 SARS-CoV-2 variants emerged and spread rapidly into the world. We analysed the RT-PCR cycle threshold values of 643 nasopharyngeal samples of COVID-19 patients at diagnosis and found that the 501Y.V2 variant presented an intermediate viral load between the 501Y.V1 and the historical variants**.**

Introduction

By the end of 2020, novel SARS-CoV-2 variants emerged and led to a strong increase of SARS-CoV-2 positive cases, the 501Y.V1 (lineage B1.1.7) in the United Kingdom (UK)[1] and the 501Y.V2 (lineage B1.351) in South Africa (SA)[2]. These variants have spread rapidly in other countries and notably present specific genetic patterns in the gene encoding the Spike protein (S).

It has been established that the N501Y mutation located in the receptor binding domain (RBD), and found in the 501Y.V1 and 501Y.V2 variants, conferred a stronger affinity with the angiotensin-converting enzyme 2 (ACE2) receptor and led to a better infectivity[3].

It was estimated that the 501Y.V1 presented a greater infectivity (up to 70%) and recent studies have shown a higher viral load for the 501Y.V1 as compared to the historical SARS-CoV-2[4,5]. It is established that the viral load is associated with the virus transmissibility[6] suggesting that 501Y.V1 higher viral load favoured its transmission.

Currently, few data are available on the viral load of the 501Y.V2, which is not fully widespread in the world. In France, these two variants are actively spreading into the population since late January and currently representing up to 70% of the new positive cases for the 501Y.V1 and 6% for the 501Y.V2 in Paris area.

In this study, we compared the viral load of the 501Y.V2, with others SARS-CoV-2 variants: the 501Y.V1 and the historical SARS-CoV-2 variants.

Methods

Dataset (cycle threshold (Ct) values, age, and sex) analysed in this retrospective study were collected from three hospital laboratories in Paris (Pitié-Salpêtrière Hospital,

Bichat-Claude Bernard Hospital and Saint-Antoine/Trousseau hospitals). A total of 643 RT-PCR SARS-CoV-2 positive nasopharyngeal samples collected at diagnosis were screened to assess SARS-CoV-2 viral lineages with the TaqPath™ COVID-19 RT-PCR (ThermoFisher, Waltham, USA) and the VirSNiP SARS-CoV-2 Spike E484K (TIB Molbiol, Berlin, Germany). The TIB Molbiol assay allowed the detection of the E484K mutation for the screening of the 501Y.V2 variant. The multi-target TaqPath COVID-19 test amplified three target genes of the virus (ORF1ab, N, and S gene). The 501Y.V1 presents a specific deletion in the S gene, *69-70del*, which results in a failure of the detection of the S gene by this assay [7]. Then, a Sanger sequencing with specific primers amplifying the RBD region was realised to confirm the variant screening and principally the distinction between the 501Y.V2 and one of the new variant, B1.1.248, carrier of the N501Y and E484K mutations. We have selected infected patients with a detected signal for the two gene targets (ORF1ab and N genes) resulting in three groups since the 20th December 2020.

Raw Ct values for the ORF1ab and N gene targets of the TaqPath assay were compared between these three groups. ANOVA with a multiple comparison test was performed with the STATVIEW software.

Results

We analysed the results from 643 SARS-CoV-2 infected patients between 20th December 2020 and 26th February 2021. We identified 332 historical SARS-CoV-2 characterised by a signal detection for the 3 target genes and absence of the E484K mutation, 249 501Y.V1 characterised by the lack of detection for the S gene and the E484K mutation and 62 501Y.V2 with a signal detection for the 3 target genes and a signal for the E484K mutation. The patients infected by these lineages presented similar median age at 57 years [38-76] and sex ratio with 53% of female patients. The median Ct value for the N gene was 21.69 [18.43-26.33] for the 501Y.V2 and was statistically different from the 501Y.V1 (median: 19.48 [16.19-25.66]) and the historical SARS-CoV-2 (median: 22.78 [19.17-38.45]) ($p<0.0001$) (figure 1A). For the ORF1ab gene, we observed a significant difference between the 501Y.V2 (median: 20.62 [17.50-25.94]) and the historical SARS-CoV-2 (median: 21.79 [18.08-27.75]) ($p<0.005$). A statistical difference was also observed between the 501Y.V1 (median:

20.13 [16.50-26.01]) and the historical SARS-CoV-2 (median: 21.79 [18.08-27.75]) ($p<0.0001$). Unlike the N gene, no statistical difference was found between the 501Y.V2 and the 501Y.V1 for the ORF1ab gene (Figure 1B).

As the Ct value is inversely proportional to the viral load, our results suggest that the 501Y.V2 is associated with higher viral loads than the historical SARS-CoV-2 but slightly lower than the 501Y.V1.

Discussion

Our results showed significant differences of the Ct values for the ORF1ab and N target genes between the three analysed SARS-CoV-2 variants. Indeed, we found that both new 501Y.V1 and 501Y.V2 variants have statistically higher nasopharyngeal viral loads at diagnosis than the historical lineages. The 501Y.V2 variant appears to present equivalent or slightly lower viral loads than the 501Y.V1 variant.

The RT-PCR Ct values can be used as a proxy of the viral load and reflect the patient's infectiousness[8] or can give information about the outcome (adverse effect and severity) of the disease in SARS-CoV-2 positive patients . Indeed, it has been shown that a low Ct value at the first SARS-CoV-2 RT-PCR testing can be used as a predictive indicator of the disease[8,9]. In the current work, a single RT-q PCR assay has been used for all patients, allowing to reliably compared the Ct values between the SARS-CoV-2 variants. Further studies are required to confirm the potential higher infectiousness and higher severity of the disease caused by these two emerging variants, as well as to understand the related cellular mechanism. However, our study reinforces the hypothesis that the 501Y.V1 variant is more infectious than the historical SARS-CoV-2[4,5] and thorough this hypothesis for the 501Y.V2 which begins to spread in France.

In addition, it has been shown that the kinetic of the viral load was more strongly associated to disease severity and mortality[9]. A Low Ct value at presentation time could be associated with a longer viral persistence of the virus and of the contagious condition of the patient as recently reported[5]. It would be necessary to explore the viral load kinetic for these variants to further explore their severity and confirm these observations made on previous lineages.

Our study is limited by the fact that we were focused on one type of data, the Ct value, which could be influenced by the variation of the nasopharyngeal swab technique or by the timeline of the epidemic. With the aim to limit this fluctuation, we only collected Ct values for the first presentation test and with the same SARS-CoV-2 assay at the same period (20th December 2020 to 26th February 2021). Another limitation is the small number of positive cases for the 501Y.V2 compared to the two other strains. This number was principally due to the only few positive cases in Paris area at that time.

Our data observed a gradient in Ct values. Indeed, the two new variants seem to present a higher viral load compared to the historical SARS-CoV-2 which might arise from the fact that they share the same N501Y mutation probably leading to a better infectivity [2,3,10]. When we compared these two variants, we observed that the 501Y.V2 seems to be associated with lower viral load compared to the 501Y.V1 for the N target gene, a difference which fades for the ORF1ab target gene. The difference of Ct values that we have observed could be due to their other specific mutations. Considering the 501Y.V2, it does not seem that the Spike RBD has higher affinity for ACE2 as compared to the reference Spike. If indeed the transmission is enhanced, this could be due to mutation outside the direct ACE2–Spike interface[11]. Moreover, it has been shown that an active viral replication was associated with the transcription of subgenomic viral RNA and that this active replication occurs during the first days after the onset of symptoms[12]. As we collected only the first presentation test sample, which suggest the presence of an active viral replication, the difference between the N and the ORF1ab genes for these two new variants could be explained by the presence of these subgenomic viral RNA.

Our study brings evidence of increased infectivity for the 501Y.V1 and new proofs for the little-known 501Y.V2 variant infectivity that could explain their propagation velocity worldwide.

Conflict of Interest

Authors declare that they have no competing interests.

Acknowledgements

The authors acknowledged all the member of the Pitié-Salpêtrière, Bichat and Saint-Antoine/Trousseau Virology departments for their collaboration and clinicians of the

three hospitals for their implication in the SARS-CoV-2 patient care. We thank the ANRS-MIE (Agence Nationale de Recherches sur le SIDA et les hépatites virales-Maladies Infectieuses Emergentes) (AC43, Medical Virology) for its support.

References

1. covid19-33-en-210112.pdf. Available at: https://www.niid.go.jp/niid/images/epi/corona/covid19-33-en-210112.pdf. Accessed 1 March 2021.

2. Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. Epidemiology, 2020. Available at: http://medrxiv.org/lookup/doi/10.1101/2020.12.21.20248640. Accessed 25 February 2021.

3. Chen J, Wang R, Wang M, Wei G-W. Mutations Strengthened SARS-CoV-2 Infectivity. J Mol Biol **2020**; 432:5212–5226.

4. Kidd M, Richter A, Best A, et al. S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR. J Infect Dis **2021**; Available at: https://doi.org/10.1093/infdis/jiab082. Accessed 25 February 2021.

5. Calistri P, Amato L, Puglia I, et al. Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs. Int J Infect Dis **2021**; 0. Available at: https://www.ijidonline.com/article/S1201-9712(21)00210-1/abstract. Accessed 9 March 2021.

6. Marks M, Millat-Martinez P, Ouchi D, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect Dis **2021**; :S1473309920309853.

7. The S Gene Advantage: TaqPath COVID-19 Tests May Help Early Identification of B.1.1.7. 2021. Available at: https://www.thermofisher.com/blog/ask-a-scientist/the-s-gene-advantage-taqpath-covid-19-tests-may-help-early-identification-of-b-1-1-7/. Accessed 25 February 2021.

8. Bullard J, Dust K, Funk D, et al. Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples. Clin Infect Dis **2020**; 71:2663–2666.

9. Néant N, Lingas G, Hingrat QL, et al. Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. Proc Natl Acad Sci **2021**; 118. Available at: https://www.pnas.org/content/118/8/e2017962118. Accessed 3 March 2021.

10. Report-1_COG-UK_19-December-2020_SARS-CoV-2-Mutations.pdf.

11. Villoutreix BO, Calvez V, Marcelin A-G, Khatib A-M. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2–Spike RBD Interface. Int J Mol Sci **2021**; 22. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915722/. Accessed 5 March 2021.

12. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature **2020**; 581:465–469.



Figure 1: 501Y.V2 and 501Y.V1 are associated with a higher viral load than historical SARS-CoV-2.

The graph presents the median and the minimal to maximal Ct values of the three groups for the N gene (A) and for the ORF1ab gene (B). The median of the Ct values was lower for the 501Y.V2 and the 501Y.V1 than the historical SARS-CoV-2. **p<0.005; ****p<0.0001.